High mortality among older patients treated with pentavalent antimonials for visceral leishmaniasis in East Africa and rationale for switch to liposomal amphotericin B

Chappuis, François; Alirol, Emilie; Worku, Dagemlidet T; Mueller, Yolanda; Ritmeijer, Koert

doi:10.1128/AAC.01298-10

Scientific article

Letter

English

High mortality among older patients treated with pentavalent antimonials for visceral leishmaniasis in East Africa and rationale for switch to liposomal amphotericin B

ContributorsChappuis, François; Alirol, Emilie; Worku, Dagemlidet T; Mueller, Yolanda; Ritmeijer, Koert

Published inAntimicrobial agents and chemotherapy, vol. 55, no. 1, p. 455-456

Publication date2011

Keywords

Africa
Age Factors
Amphotericin B/therapeutic use
Antiprotozoal Agents/therapeutic use
Humans
Leishmaniasis, Visceral/drug therapy/mortality
Middle Aged

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de santé et médecine communautaires / Institut de médecine de premier recours

Research groups

Groupe Louis Loutan (médecine des Voyages et des Migrations, Médecine Tropicale, Santé Internationale) (122)

Citation (ISO format)

CHAPPUIS, François et al. High mortality among older patients treated with pentavalent antimonials for visceral leishmaniasis in East Africa and rationale for switch to liposomal amphotericin B. In: Antimicrobial agents and chemotherapy, 2011, vol. 55, n° 1, p. 455–456. doi: 10.1128/AAC.01298-10

Article (Published version)

Identifiers

PID : unige:25190
DOI : 10.1128/AAC.01298-10
PMID : 21078947

Journal ISSN0066-4804

634views

367downloads

Creation29/10/2012 12:58:00

First validation29/10/2012 12:58:00

Update14/03/2023 19:54:47

Status update14/03/2023 19:54:46

Last indexation30/10/2024 08:18:20

Archive ouverte UNIGE

High mortality among older patients treated with pentavalent antimonials for visceral leishmaniasis in East Africa and rationale for switch to liposomal amphotericin B

Technical informations